Table 1. Clinicopathological features of the 129 patients and the tumor tissue samples.

Variable	No. (%)	The mRNA expression of S100A6 (mean ± SD)	P value
Gender			P = 0.461
Male	90(69.8)	0.028 ± 0.004
Female	39(30.2)	0.033 ± 0.007
Age(year)			P = 0.526
≤40	22(17.1)	0.026 ± 0.009
>40, ≤60	78(60.4)	0.033 ± 0.005
>60	29(22.5)	0.023 ± 0.006
BMI			P = 0.832
<25	85(65.9)	0.025 ± 0.013
≥25	44(34.1)	0.031 ± 0.022
Tumor size(cm)			P = 0.0003***
≤4	62(48.1)	0.021 ± 0.004
>4, ≤7	51(39.5)	0.030 ± 0.006
>7	16(12.4)	0.054 ± 0.017
Fuhrman			P = 0.037*
I	26(20.2)	0.021 ± 0.0047
II	82(63.6)	0.026 ± 0.0045
III	19(14.7)	0.048 ± 0.012
IV	2(1.5)	0.109 ± 0.064
TNM Stage			P = 0.0002***
I	106(82.1)	0.237 ± 0.004
II	5(3.9)	0.029 ± 0.022
III	10(7.8)	0.032 ± 0.015
IV	8(6.2)	0.91 ± 0.016
Metastatic status			P = 0.0014**
NM	111(86.0)	0.024 ± 0.004
LM	8(6.2)	0.082 ± 0.024
DM	10(7.8)	0.051 ± 0.016

TNM Stage: TNM stage grouping was according to the 2009 TNM staging classification system. Stage I: T₁N₀M₀, Stage II: T₂N₀M₀, Stage III: T₃N₀(N₁)M₀, T₁(T₂)N₁M₀, Stage IV: T₄N_0–2M₀, T_1–4N₂M₀, T_1–4N_0–2M₁. Abbreviation: BMI: body mass index; NM tumors involving non-metastasis; LM: tumors involving lymphatic metastasis; HM: tumors involving distant organ metastasis. Statistical analysis were described in Materials and Methods.